<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE333nnn/GSE333837/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE333837</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Phosphorylation-dependent regulation of gene expression and alternative splicing by THRAP3 in prostate cancer</name><description>Prostate cancer (CaP) is a leading cause of cancer deaths in American men. Searching for novel treatments, we uncovered a critical role for the poorly characterized mitotic citron kinase (CIT) in CaP growth and tumorigenicity. Thyroid Hormone Receptor-Associated Protein 3 (THRAP3) is an RNA-binding protein implicated in mRNA splicing, stability, and DNA damage response that our prior studies identified as a CIT substrate. THRAP3 silencing and overexpression diminished and increased, respectively, CaP cell proliferation, mimicking CIT’s effects. We then identified the several THRAP3-bound transcripts, one of which is CPT1A. CPT1A was found to be alternatively spliced by THRAP3 in prostate cancer cells generating a catalytically inactive, alternatively spliced variant, CPT1A-v2, while having no effect on the conventional active variant, CPT1A-v1. We demonstrate the therapeutic potential of disrupting the THRAP3-RNA binding via RNA decoys and antisense oligonucleotides (ASOs) which resulted in reduced synthesis of the oncogenic variant of CPT1A-v2 and thereby reduced growth of prostate cancer cells and patient-derived organoids (PDOs). In addition, overexpression of the oncogenic splice variant, CPT1A-v2 increased the prostate cancer cell growth, xenograft tumor volume and PDO growth, while CPT1A-v2 overexpression had either no or opposite effects. Targeting the synthesis of such variants by disrupting the THRAP3-RNA binding, therefore, may provide fresh therapeutic perspectives. These findings define a novel mechanism by which CIT rewires alternative splicing in CaP and present new therapeutic opportunities for targeting aggressive CaP.</description><dates><publication>2026/08/25</publication></dates><accession>GSE333837</accession><cross_references><GSM>GSM9775762</GSM><GSM>GSM9775751</GSM><GSM>GSM9775763</GSM><GSM>GSM9775752</GSM><GSM>GSM9775760</GSM><GSM>GSM9775761</GSM><GSM>GSM9775750</GSM><GSM>GSM9775759</GSM><GSM>GSM9775748</GSM><GSM>GSM9775749</GSM><GSM>GSM9775768</GSM><GSM>GSM9775757</GSM><GSM>GSM9775746</GSM><GSM>GSM9775747</GSM><GSM>GSM9775758</GSM><GSM>GSM9775766</GSM><GSM>GSM9775755</GSM><GSM>GSM9775767</GSM><GSM>GSM9775756</GSM><GSM>GSM9775745</GSM><GSM>GSM9775764</GSM><GSM>GSM9775753</GSM><GSM>GSM9775765</GSM><GSM>GSM9775754</GSM><GPL>34284</GPL><GPL>24676</GPL><GSE>333837</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>